Appili Therapeutics Announces Proposed Non-Brokered Private Placement

Executive Summary

• Appili Therapeutics announced a non‑brokered private placement of up to 30,000,000 units at C$0.025 per unit, targeting gross proceeds of approximately C$750,000.
• Each unit consists of one Class A common share and half of a common‑share purchase warrant (exercise price C$0.05, 36‑month term, subject to shareholder approval).
• Net proceeds will be used primarily for working capital and the development of the company’s product candidates; closing is expected in November 2025.

Key Details

• Units Offered: Up to ~30,000,000 units at C$0.025 per unit.
• Aggregate Gross Proceeds: Approximately C$750,000 (subject to full subscription).
• Unit Composition: 1 Class A common share + ½ warrant (each whole warrant allows purchase of one common share at C$0.05 for 36 months).
• Warrant Conditions: Exercisable only after shareholder approval obtained no later than the next Annual General Meeting; holders of warrants excluded from voting on that approval.
• Use of Proceeds: Primarily working capital and funding development of selected product candidates.
• Closing Timeline: Anticipated closing in November 2025, subject to regulatory approvals (including TSX).
• Finder’s Fee: 8.0% of gross proceeds payable in cash to certain finders.
• Broker Warrants: Equal to 8.0% of the number of units issued; each confers the right to purchase one common share at a price not less than C$0.02834 for 24 months, also subject to shareholder approval under the same conditions as the primary warrants.
• Statutory Hold Period: All securities issued will be subject to a hold period of four months and one day from issuance.

Notable Quotes

(No executive quotes were included in the release.)